Carcinoid tumour

Minerva Medica

Volumn 93, Issue 5, 2002, Pages 389-401

  McStay, M K G ^a   Caplin, M E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Carcinoid tumor, therapy; Carcinoid tumour, diagnosis; Neuroendocrine tumors

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; CHROMOGRANIN A; FLUORODEOXYGLUCOSE F 18; GASTRIN; HISTAMINE; KALLIKREIN; LANREOTIDE AUTOGEL; NEUROKININ A; OCTREOTIDE; PENTETREOTIDE IN 111; PROSTAGLANDIN; RECOMBINANT INTERFERON; SEROTONIN; SOMATOSTATIN DERIVATIVE; SOMATULIN LA; SUBSTANCE P; TUMOR MARKER; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; YTTRIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; YTTRIUM 90;

ABDOMINAL PAIN; ARTIFICIAL EMBOLISM; CANCER IMMUNOTHERAPY; CANCER SURGERY; CARCINOID; CATHETER ABLATION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE ASSOCIATION; FLUSHING; GALLSTONE; HEART DISEASE; HUMAN; INJECTION SITE; LIVER METASTASIS; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PAIN; PATHOPHYSIOLOGY; PELLAGRA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SIDE EFFECT; TELANGIECTASIA; TUMOR DIAGNOSIS; TUMOR SCINTISCANNING; WHEEZING;

CARCINOID TUMOR; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; OCTREOTIDE; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036819325     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Solcia E, Capella C, Buffa R, Usellini L, Fiocca R, Sessa F. Endocrine cells of the digestive system. In: Johnson LR, editor. Physiology of the Gastrointestinal Tract. New York: Raven Press, 1981:39-58.
2. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;i:238-9.
3. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001;12(9):1295-300.
4. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 2000;83(7):952-5.
5. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79(4):813-29.
6. Hodgson HJF. Carcinoid tumours and the carcinoid syndrome. In: Bonchier IAD, Allan RN, Hodgson HJF, Keighley MRB, editors. Gastroenterology: Clinical Science and Practice. London: WB Saunders, 1993:643-58.
7. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62(Suppl 1);51-8.
8. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998;352:799-805.
9. Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol 1907;1:426-9.
10. Rindi G, Villanaci A, Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 2000;62(Suppl 1):19-26.
11. Soga J, Tazawa K. Pathologic analysis of carcinoids. Cancer 1971;28:990-8.
12. DeLellis RA, Dayal Y, Wolfe HJ. Carcinoid tumours: Changing concepts and new perspectives. Am J Surg Pathol 1984;8:295-300.
13. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropathic tract. Q J Nucl Med 2000;44(1):13-21.
14. Norheim I, Norheim-Theodorsson E, Brodin E, Öberg K. Tachykinins in carcinoid tumours: Their use as a tumour marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605-12.
15. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-7.
16. Bystrom C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B et al. Localisation of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Sci USA 1990; 87:1968-72.
17. Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
18. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997;276:404-7.
19. European Consortium on MEN 1. Identification of the multiple endocrine neoplasia type 1 (MEN 1) gene. Hum Mol Genet 1997;6:1177-83.
20. Karim M, Liu Z, Zandi E. AP1 function and regulation. Curr Opin Cell Biol 1997;9:240-6.
21. Calender A. Molecular genetics of neuroendocrine tumours. Digestion 2000;62(Suppl 1):3-18.
22. Ahlman H, Wängberg B, Jansson S, Friman S, Olausson M, Tylén U et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62(Suppl 1):59-68.
23. Warburton R, Keevil B. Urinary 5-hydroxyindole-acetic acid by high performance liquid chromatography with electrochemical detection. Ann Clin Biochem 1997;34:424-6.
24. Janson ET, Holmberg L, Stridsberg M, Erikson B, Theodorsson E, Wilander E et al. Carcinoid tumours. Analysis of prognostic factors and survival in 301 patients from a referral centre. Ann Oncol 1997;8:685-90.
25. Iacangelo AL, Eiden LE. Chromogranin A: Current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995;58:65-88.
26. Öberg K. Neuroendocrine gastrointestinal tumours: A condensed overview of diagnosis and treatment. Ann Oncol 1999;10(Suppl 2):S3-8.
27. Anthony LB, Martin W, Delbeke D, Sandler M. Somatostatin receptor imaging: Predictive and prognostic considerations. Digestion 1996;57(Suppl 1):50-3.
28. Cwila JB, Buscombe JR, Mielcarek WA, Caplin ME, Watkinson AJ, Hilson AJW. Comparison of functional imaging and standard CT in evaluation of disease extent in patients with tumours showing neuroendocrine features. Nucl Med Rev 2001;4(1):27-33.
29. Chow A, Caplin ME, Buscombe JR, Hilson AJW. Somatostatin receptor scintigraphy in neuroendocrine tumours: Is single photon emission tomography SPECT) required? Gut 2001;48(Suppl 1):A186.
30. 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A(11):1924-32.
31. Ricke J, Klose K. Imaging procedures in neuroendocrine tumours. Digestion 2000;62(Suppl 1):39-44.
32. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja Langstrom B et al. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumours. J Clin Oncol 1998;16(7):2534-41.
33. 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med 2000;28(12):1751-7.
34. Norton JA. Surgical management of carcinoid tumours: Role of debulking and surgery for patients with advanced disease. Digestion 1994;55(Suppl 3):98-103.
35. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumour of the small intestine. Cancer 1961;14:901.
36. Madridis C, Öberg K, Juhlin C, Rastad J, Johansson H, Lörelius LE et al. Surgical treatment of midgut carcinoid tumours. World J Surg 1990;14:377-85.
37. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumours. Acta Oncol 1991;30:547.
38. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumours of the vermiform appendix. Cancer 1968;21:270-5.
39. Caplin ME, Hodgson HJ, Dhillon AP, Begent R, Buscombe J, Dick R et al. Multimodality treatment for gastric carcinoid tumor with liver metastases. Am J Gastroenterol 1998;93(10):945-8.
40. Ahlmann H, Kölby L, Lundell L, Olbe L, Wängberg B, Granérus G et al. Clinical management of gastric carcinoid tumours. Digestion 1994;55(Suppl 3):77-85.
41. Rothmund M, Kisker O. Surgical treatment of carcinoid tumours of the small bowel, appendix, colon and rectum. Digestion 1994;55(Suppl 3):86-91.
42. Sauven P, Ridge JA, Quan SH, Sigurdson ER. Anorectal carcinoid tumours: Is aggressive surgery warranted? Ann Surg 1990;211(1):67-71.
43. Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM. Carcinoid tumors of the rectum: Effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997;79(7):1294-8.
44. Dusmet ME, McKneally MF. Pulmonary and thymic carcinoid tumours. World J Surg 1996;20:189-95.
45. Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumours: The place of somatostatin analogues. Digestion 1995;55:107-13.
46. Öberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001;47(Suppl 2):40-53.
47. Dowling R, Hussaini S, Murphy G, Besser GM, Wass JA. Gallstones during octreotide therapy. Metabolism 1992;41(9 Suppl 2):22-33.
48. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 2000;62(Suppl 1):84-91.
49. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000;190(4):432-45.
50. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999;10(4):397-403.
51. Chuang VP, Wallace S. Hepatic artery embolisation in the treatment of hepatic neoplasms. Radiology 1981;140:51-8.
52. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Digestion 2000;62(Suppl 1):79-83.
53. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001;95(1):8-12.
54. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: Lessons learned. Oncologist 2001;6(1):24-33.
55. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumours. A 31-case French multicentric report. Ann Surg 1997;225(4):355-64.
56. Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P et al. Liver transplantation for neuroendocrine tumours. Ann Surg 1997;225(4):347-54.
57. Jamil A, Taylor-Robinson S, Millson C, Gimson A, Buckels J, Hudson M et al. Orthotopic liver transplantation for the treatment of metastatic neuroendocrine tumours-analysis of all UK patients. Presented at the British Association for the Study of the Liver Annual Meeting, September 2001.
58. Moertal CG. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-22.
59. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumours. Digestion 2000;62 (Suppl 1):73-8.
60. 131I-meta-iodo-enzylguanindine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 2000;44(1):77-87.
61. 131I-metaiodobenzylguanidine. Clin Endocrinol 2001;55(1):47-60.
62. 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun 2000;21(8):755-61.
63. 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol 1999;11(10):1157-64.
64. 111In-pentetreotide: Initial observations and future directions. Cancer J Sci Am 1998;4(2):92-102.
65. 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000;21(1):97-102.
66. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001;12(7):941-5.
67. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: Effect on tumour growth in metastatic endocrine gastroenteropancreatic tumours. Am J Gastroenterol 1999;94(5):1381-7.
68. Öberg K. Interferon in the management of neuroendocrine GEP-tumours. Digestion 2000;62(Suppl 1):92-97.
69. Olney JR, Urdaneta LF, Al-Jurf AS, Jochimsen PR, Shirazi SS. Carcinoid tumours of the gastrointestinal tract. Am Surg 1985;51(1):37-41.
70. Mignon M. Natural history of neuroendocrine enteropancreatic tumours. Digestion 20000;62(Suppl 1):51-8.